Real World Evidence Study of SYN023 in Children Exposed to Rabies

Recruiting Observational Study
Rabies Post-exposure Prophylaxis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 – 17
Sex
Any
Study type
Observational
Participants needed
232 (estimated)
Sponsor
Synermore Biologics (Suzhou) Co., Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This observational study is an open-label, prospective, multi-center design. The goal is to evaluate the long-term clinical survival outcomes at 3 months and 1 year in individuals under 18 years of age with WHO Category III rabies exposure who have received real-world Post-Exposure Prophylaxis (PEP) with Zamerovimab and Mazorelvimab Injection / other passive immunization products combined with the…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age under 18 years on the day of enrollment, regardless of gender, and able to provide legal proof of identity; 2. Individuals with WHO Category III rabies exposure, and the time from exposure to the initiation of Post-Exposure Prophylaxis (PEP) is \<7 days; 3. Have completed…
Contacts

Xiangjun Li

+86 0512-8765807

xjli@synermore.cn

CONTACT